Sorafenib is a multi-targeted tyrosine kinase inhibitor, with antiangiogenic and antiproliferative properties, approved for the treatment of advanced hepatocellular carcinoma. It induces a significant increase in the median overall survival, despite a complete response to treatment being rare. We report a clinical case of a 60-year-old male with hepatic cirrhosis, Child-Pugh class A and performance status 0, an...
Sorafenib is a multi-targeted tyrosine kinase inhibitor, with antiangiogenic and antiproliferative properties, approved for the treatment of advanced hepatocellular carcinoma. It induces a significant increase in the median overall survival, despite a complete response to treatment being rare. We report a clinical case of a 60-year-old male with hepatic cirrhosis, Child-Pugh class A and performance status 0, an...
A síndromedeChurg-Strauss(SCS)éumavasculitesistémicanecrotizante,queafeta os vasosdepequenoemédiocalibreeseassociaagranulomaseosinofílicosextravasculares, eosinofilia periféricaeasma. É umasíndromerara,deetiologiadesconhecidaequeafetaambososgénerosetodosos grupos etários. Os doentescomSCSgeralmenteapresentamboarespostaàterapêuticacomglucocorticoi- des, emboraasrecidivassejamfrequentesapósasuasuspensão.Odiagnóst...